市場調查報告書

全球恆溫核酸增幅技術(INAAT)市場:各技術、用途、地區 - 成長,趨勢,預測(2018年∼2023年)

Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 390904
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球恆溫核酸增幅技術(INAAT)市場:各技術、用途、地區 - 成長,趨勢,預測(2018年∼2023年) Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market - Segmented by Technology, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年05月01日內容資訊: 英文 112 Pages
簡介

全球恆溫核酸增幅技術(INAAT)市場,預計從2018年到2023年的預測期間記錄10.5%的年複合成長率。

本報告提供全球恆溫核酸增幅技術(INAAT)市場調查,市場概要,各技術、用途、地區的市場規模的變化與預測,市場成長要素、阻礙因素以及市場機會、課題分析,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 分子診斷的劇增
    • 慢性疾病的罹患率的上升和高齡化
    • 與PCR(聚合酶鏈反應法)比較,INAAT的採用增加
  • 市場阻礙因素
    • PCR技術的威脅
    • 新診斷技術的認知度不足
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各技術
    • HDA法
    • NEAR法
    • LAMP法
    • SDA法
    • NASBA法
    • TMA法
    • SPIA法
    • 其他
  • 各用途
    • 腫瘤
    • 研究調查
    • 診斷
    • 血液篩檢
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Alere, Inc.
  • Becton, Dickinson & Company
  • BioHelix
  • bioMerieux
  • Hologica
  • New England Biolabs
  • Nugen
  • Qiagen
  • Quidel Corporation
  • 清單未完全網羅

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49281

The global isothermal nucleic acid amplification technology (INAAT) market is expected to register a CAGR of 10.5%, during the forecast period, (2018-2023). North America dominates the market, due to technological advancement and growing awareness regarding INAAT technique among end-user in the region.

Rise in the Miniaturization of Nucleic Acid based Diagnostics

Miniaturization of biochemical reactions leads to major advantages, where a lower amount of valuable clinical sample and reagents is just one: approximately 1/1000 of the volume used in conventional lab setups has been shown to obtain a similar result. A smaller heat capacity allows for rapid changes in temperature beneficial for the PCR time, as well as a higher parallelism of multiple genetic samples. The benefit of isothermal amplification methods compared to PCR is the constant temperature of amplification. This will result in a high potential for a simple integration in point-of-care devices and a reduction of complexity. With increasing demand of low cost and effective solutions for diagnosis of diseases and increasing demand for point of care applications, these devices are going to witness growth in the future. Also in case of laboratories the sample size required is very small which also helps in reducing the amount of reagents required. Also, the upsurge in the molecular diagnostics market, increasing incidences of chronic diseases and aging population, and increase in the adoption of INAAT over PCR are driving the market growth.

Stringent regulatory framework

In the expanding market for medical devices and therapies, there are stringent regulatory policies in place to ensure the safety of such drugs and devices. These policies are well studied. However, while rigorous regulatory procedures guarantee the quality of the product entering the market, they delay the entry of a drug or device into the market, which could be beneficial to all patients suffering from a disease. Pre-market approval is an FDA process of scientific and regulatory review to evaluate the safety and effectiveness of drugs and devices. There have been procedures by the FDA to heighten the post-market surveillance. The FDA review process takes twice as much as time as European regulatory commissions review bodies. Hence, citizens from countries where the review process is shorter benefit more than countries with longer review processes and stringent regulations. The presence of stringent regulations is dampening the innovation in the market and hindering the growth of this market. Strict regulatory policies have resulted in a reduction of investment by drug companies in R&D of new products. Also the lack of awareness in new diagnostics technologies may induce users to stick to conventional methods, although this can be addressed with effective marketing

North America to Dominate the Market

North America dominates the Isothermal Nucleic Acid Amplification Technology (INAAT) market, owing to high incidence of chronic diseases, technological advancement in isothermal nucleic acid amplification technology (INAAT), and increasing adoption of INAAT over conventional techniques in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high demand in cost effective and diagnostics, less stringent regulatory scenario, and presence of huge population base.

Key Developments in the Market

March 2017: Alere Inc. a global leader in rapid diagnostic tests, announced that the U.S. Food and Drug Administration (FDA) has granted CLIA waiver for the Alere i Strep A test

Major Players: ALERE, BECTON, DICKINSON & COMPANY, BIOMERIUX, HOLOGICA, LUCIGEN, QUIDEL CORPORATION, NEW ENGLAND BIOLABS, NUGEN, QIAGEN, USTAR BIOTECHNOLOGIES, amongst others.

Reasons to Purchase this Report

Current and future global isothermal nucleic acid amplification technology outlook, in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness the fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Upsurge in the Molecular Diagnosis
    • 6.1.2 Increasing Incidences of Chronic Diseases and Aging Population
    • 6.1.3 Increase in the Adoption of INAAT over PCR
    • 6.1.4 Rise in the Miniaturization of Nucleic Acid Based Diagnosis
  • 6.2 Market Restraints
    • 6.2.1 Threatening Opposition from PCR Technologies
    • 6.2.2 Lack of Awareness of New Diagnostics Technologies
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Technology
    • 7.1.1 Helicase-dependent Amplification (HDA)
    • 7.1.2 Nicking Enzyme Amplification Reaction (NEAR)
    • 7.1.3 Loop-mediated Isothermal Amplification (LAMP)
    • 7.1.4 Strand Displacement Amplification (SDA)
    • 7.1.5 Nucleic Acid Sequence Based Amplification (NASBA)
    • 7.1.6 Transcription Mediated Amplification (TMA)
    • 7.1.7 Single Primer Isothermal Amplification (SPIA)
    • 7.1.8 Others
  • 7.2 By Applications
    • 7.2.1 Oncology
    • 7.2.2 Laboratory Research
    • 7.2.3 Diagnostics
    • 7.2.4 Blood Screening
    • 7.2.5 Others
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest Of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East & Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of the Middle East & Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Alere, Inc.
  • 9.2 Becton, Dickinson & Company
  • 9.3 BioHelix
  • 9.4 bioMerieux
  • 9.5 Hologica
  • 9.6 New England Biolabs
  • 9.7 Nugen
  • 9.8 Qiagen
  • 9.9 Quidel Corporation
  • 9.10 List Not Exhaustive

10. Future of the Market